889
Participants
Start Date
April 30, 2011
Primary Completion Date
January 31, 2013
Study Completion Date
January 31, 2013
Duloxetine
Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
Placebo matching with BMS-820836
Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
BMS-820836
Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
Duloxetine
Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
Placebo matching with Duloxetine
Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
Local Institution, Vereeniging
Local Institution, Johannesburg
Local Institution, Somerset West
Local Institution, Cape Town
Local Institution, Bellville
SPRI Clinical Trials, LLC, Brooklyn
Neurobehavioral Research, Inc., Cedarhurst
Finger Lakes Clinical Research, Rochester
Lehigh Center For Clinical Research, Allentown
Univ Of Penn, Philadelphia
University Of Pennsylvania, Philadelphia
University Of Pennsylvania, Philadephia
Thomas Jefferson University, Philadelphia
Belmont Center For Comprehensive Treatment, Philadelphia
Local Institution, Turku
Richard H. Weisler, Md, Pa & Assoc., Raleigh
Carolina Clinical Research Services, Columbia
University Of South Carolina School Of Medicine, Columbia
Carman Research, Smyrna
Atlanta Institute Of Medicine & Research, Atlanta
Comprehensive Clinical Development, Inc., Atlanta
Local Institution, Nîmes
Clinical Neuroscience Solutions, Inc., Jacksonville
Clinical Neuroscience Solutions, Inc., Orlando
Compass Research, Llc, Orlando
Local Institution, Tampere
Comprehensive Clinical Development, Inc., St. Petersburg
Local Institution, Montpellier
Psychiatric Consultants, Pc, Franklin
Clinical Neuroscience Solutions, Inc., Memphis
Local Institution, Dole
Midwest Clinical Research Center, Dayton
Alpine Clinic, Lafayette
Independent Psychiatric Consultants, Sc, Dba, Ipc Research, Waukesha
Northbrooke Research Center, Brown Deer
Dean Foundation For Health Research & Education, Middleton
Local Institution, Douai
Local Institution, Seinäjoki
Loyola University Health System, Maywood
Clinical Trials Technology, Inc, Prairie Village
James G. Barbee, Md, Llc, New Orleans
K & S Professional Research Services, Llc, Little Rock
Ips Research Company, Oklahoma City
Tulsa Clinical Research, Llc, Tulsa
Local Institution, Paris
Uthealth - Houston, Houston
Red Oak Psychiatry Associates, Houston
San Antonio Psychiatric Research Center, San Antonio
Community Clinical Research, Inc., Austin
Local Institution, Élancourt
Radiant Research, Inc., Denver
Psychiatric And Behavioral Solutions, Salt Lake City
Radiant Research, Inc., Murray
Local Institution, Limoges
Local Institution, Oulu
Pharmacology Research Institute, Los Alamitos
Pacific Clinical Research Medical Group, Arcadia
Pharmacology Research Institute, Encino
California Neuroscience Research Medical Group, Inc., Sherman Oaks
Schuster Medical Research Institute, Sherman Oaks
Pacific Clinical Research Medical Group, Upland
California Neuropsychopharmacology Clinical Research Inst., San Diego
Pacific Research Network, Inc, San Diego
Pharmacology Research Institute, Newport Beach
Collaborative Neuroscience Network, Inc., Garden Grove
Oregon Center For Clinical Investigations, Inc. (Occi, Inc), Portland
Summit Research Network (Oregon) Inc, Portland
Oregon Center For Clinical Investigations, Inc (Occi, Inc), Salem
Northwest Clinical Research Center, Bellevue
Summit Research Network (Seattle) Llc, Seattle
Comprehensive Psychiatric Care, Norwich
Local Institution, Edmonton
Local Institution, Vancouver
Local Institution, Toronto
Local Institution, Montreal
Local Institution, Québec
Local Institution, Helsinki
Local Institution, Helsinki
Local Institution, Järvenpää
Local Institution, Pretoria
Local Institution, Halmstad
Local Institution, Kungens Kurva
Local Institution, Lund
Local Institution, Uppsala
Lead Sponsor
Bristol-Myers Squibb
INDUSTRY